Diligence memo · auto-generated · as of July 2, 2026
Theron Pharmaceuticals, Inc.
Theron Pharmaceuticals, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Theron Pharmaceuticals, Inc. operates in Pharmaceuticals, based in Sunnyvale.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Theron Pharmaceuticals, Inc. has raised $2.2M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $958K on 2010-05-12.
Most recent recorded round closed around 2015-07-24.
Valuation (modeled)modeled
Provath models Theron Pharmaceuticals, Inc. at approximately $19M (range $229K–$219M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.70× the median modeled value of Pre-Seed Pharmaceuticals companies in 2013–2015 (87 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 25 months.
Last raise 10.9 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.6× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 29% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 27% of those peers.
Closest niche peers: IPM Safety Services, Inc., Scioderm, LLC, Chondrial Therapeutics, LLC, OnCore Biopharma, Inc., VR1 Corp.
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.